Hoban, 2015 - Google Patents
The Potential of Neurotrophin-Secreting Mesenchymal Stem Cells for the Treatment of Parkinson's DiseaseHoban, 2015
View PDF- Document ID
- 11192919060842675752
- Author
- Hoban D
- Publication year
External Links
Snippet
The most effective experimental neuroprotectant for Parkinson's disease that has been identified from extensive preclinical studies is the neurotrophin, glial cell line-derived neurotrophic factor (GDNF). However, the efficacy of GDNF in clinical trials has been …
- 208000018737 Parkinson disease 0 title abstract description 150
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Somaa et al. | Peptide-based scaffolds support human cortical progenitor graft integration to reduce atrophy and promote functional repair in a model of stroke | |
| US12241084B2 (en) | Methods for efficient generation of GABAergic interneurons from pluripotent stem cells | |
| Chen et al. | Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson's disease | |
| Corti et al. | Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model | |
| Marei et al. | Human olfactory bulb neural stem cells expressing hNGF restore cognitive deficit in Alzheimer's disease rat model | |
| Tajiri et al. | Intravenous transplants of human adipose-derived stem cell protect the brain from traumatic brain injury-induced neurodegeneration and motor and cognitive impairments: cell graft biodistribution and soluble factors in young and aged rats | |
| Shingo et al. | Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF‐producing cells in a rat model of Parkinson's disease | |
| McCoy et al. | Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease | |
| Maisano et al. | Differentiation and functional incorporation of embryonic stem cell-derived GABAergic interneurons in the dentate gyrus of mice with temporal lobe epilepsy | |
| Lee et al. | Human fetal brain-derived neural stem/progenitor cells grafted into the adult epileptic brain restrain seizures in rat models of temporal lobe epilepsy | |
| Tanner et al. | Oligodendrocyte progenitors reversibly exit the cell cycle and give rise to astrocytes in response to interferon-γ | |
| Escande et al. | Loss of homeostasis in the direct pathway in a mouse model of asymptomatic Parkinson's disease | |
| Lei et al. | Signaling of glial cell line-derived neurotrophic factor and its receptor GFRα1 induce Nurr1 and Pitx3 to promote survival of grafted midbrain-derived neural stem cells in a rat model of Parkinson disease | |
| El-Akabawy et al. | Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington’s disease | |
| CN103561751A (en) | Generation of neural stem cells from human trophoblast stem cells | |
| Carli et al. | Is adult hippocampal neurogenesis really relevant for the treatment of psychiatric disorders? | |
| ES2796853T3 (en) | Targeted differentiation of astrocytes from human pluripotent stem cells for use in drug screening and treatment of amyotrophic lateral sclerosis (ALS) | |
| Melone et al. | Huntington's disease: new frontiers for molecular and cell therapy | |
| Marei et al. | Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease | |
| Walczak et al. | Chemobrain as a product of growing success in chemotherapy-focus on glia as both a victim and a cure | |
| Farzanehfar et al. | Evidence of functional duplicity of Nestin expression in the adult mouse midbrain | |
| Vermilyea et al. | The role of nonhuman primate models in the development of cell-based therapies for Parkinson’s disease | |
| US20210246422A1 (en) | Method to generate induced oligodendrocyte-lineage cells and treatment using such cells | |
| Beatriz et al. | Revisiting cell and gene therapies in Huntington’s disease | |
| Hoban | The Potential of Neurotrophin-Secreting Mesenchymal Stem Cells for the Treatment of Parkinson’s Disease |